-
Product Insights
GTPase KRas – Drugs In Development, 2023
Global Markets Direct’s GTPase KRas provides in depth analysis on GTPase KRas targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in GTPase KRas targeted therapeutics development and features...
-
Sector Analysis
KRAS Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
KRAS Tests Market Report Overview The KRAS tests market size was $80.4 million in 2023. The market is expected to grow at a CAGR of more than 6% during 2023-2033. Kirsten rat sarcoma virus (KRAS) gene tests are carried out to detect gene mutations in patient tissue samples. The outcome of these tests may guide therapies to treat various cancers including colorectal cancer, certain lung cancers, and some leukemias. KRAS Tests Market Outlook, 2023-2033 ($ Million) Buy the Full Report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sotorasib in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sotorasib in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sotorasib in Metastatic Colorectal Cancer Drug Details: Sotorasib (Lumakras /...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sotorasib in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sotorasib in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sotorasib in Colorectal Cancer Drug Details: Sotorasib (Lumakras / Lumykras) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INCB-161734 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INCB-161734 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INCB-161734 in Colorectal Cancer Drug Details: INCB-161734 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INCB-161734 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INCB-161734 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INCB-161734 in Solid Tumor Drug Details: INCB-161734 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INCB-161734 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INCB-161734 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INCB-161734 in Pancreatic Ductal Adenocarcinoma Drug Details: INCB-161734 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ELI-002 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ELI-002 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ELI-002 in Pancreatic Ductal Adenocarcinoma Drug Details: ELI-002 (VED-002) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ELI-002 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ELI-002 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ELI-002 in Colorectal Cancer Drug Details: ELI-002 (VED-002) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ELI-002 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ELI-002 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ELI-002 in Solid Tumor Drug Details: ELI-002 (VED-002) is under development...